It is likely that the higher antibody titers along with natural immunity may confer strong protection in these patients. in multivariate logistic regression analysis (Odds Ratio 2.35, 95% confidence interval 1.2C4.6, test was used when appropriate. Univariate and multivariate analyses were tested using logistic SSR128129E regression models. Variables with a value??0.1 in the univariate model were included in the multivariate analysis. A value??71?years, (%)382 (27.4)Male, (%)784 (56.3)ECOG 0C1 at vaccination1351 (97)Baseline disease, (%)?AML179 (12.8)?ALL46 (3.3)?MDS158 (11.3)?B-cell NHL302 (21.6)?T cell NHL38 (2.7)?Plasma cell disorders236 (16.9)?CLL158 (11.3)?HD103 (7.4)?cMPN139 (10)?Aplastic anemia16 (1)?Non-malignant disorders18 (1.3)Type of cell therapy?Allo-HSCT369 Rabbit Polyclonal to PPP1R2 (26.5)?ASCT110 (8)?CAR-T21 (1.5)Status disease at vaccination, (%)?Complete remission824 (59.2)?Partial remission162 (11.6)?Active disease408 (29.2)Time last treatment to COVID-19 vaccine, months (range)?Untreated172 (12.3)?Active treatment509 (36.5)??6?month to 1 1?year92 (6.6)??1?year621 (44.5)Immunosuppressant drugs at vaccination, (%)300 (21.5)Corticosteroids at vaccination, (%)255 (18.6)Daratumumab, (%)46 (3.3)Venetoclax, (%)14 (1)Anti-CD-20 moAb, (%)241 (17.3)??1?year before 1st vaccine dose129 (9.3)BTK inhibitor therapy, (%)63 (4.5)TKI therapy, (%)40 (2.9)Lenalidomide maintenance, (%)120 (8.6)Ruxolitinib therapy, (%)14 (1)Blood count before vaccination (?109/mL)?Absolute neutrophile counts, median (range)3.1 (0C46.7)?Absolute lymphocyte counts, median (range)1.73 (0.14C262.1)?Absolute lymphocyte counts?SSR128129E TKIs, tyrosine kinase inhibitors; and SCoV2-R-A, SARS-CoV-2-reactive IgG antibodies Overall, the SCoV2-R-A detection rate at 3C6?weeks after the complete vaccination was 78.2%. Among those with quantitative antibody testing, the median SCoV2-R-A titer was 720.26 BAU/mL (range 0C58,600). We compared SCoV2-R-A titers at 3C6?weeks after full vaccination in patients with and without SARS-CoV-2 infection prior to vaccination (excluding 7 patients with breakthrough SARS-CoV-2 infection after SSR128129E the second vaccine dose and before the first serological testing) and found higher titers in those with (median 2550 BAU/mL, range 0C10,400) vs those without (median 493.6 BAU/mL, range 0C6338.6) (valuevaluevalue
SARS-CoV-2 infection17 (3.4%)10 (1.8%)00.018Symptomatic SARS-CoV-210 (2%)3 (0.5%)00.035Pneumonia4 (0.7%)000.05Hospital admission8 (1.5%)000.012Oxygen requirement7 (1.3%)000.006ICU admission2 (0.35%)000.2Death2 (0.35%)000.2 Open in.